• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Oura Ring Detects the Onset of Fever, a Common COVID-19 Symptom

Share:

December 16, 2020

This report represents early findings from the TemPredict study, which has a goal to develop an algorithm that predicts the onset of symptoms such as fever, cough and fatigue.

Using longitudinal temperature data, wearable devices can predict the onset of illnesses even without recognizable symptoms, according to new research published in Scientific Reports.

The paper included data from only 50 participants, and researchers stressed that the findings are a proof-of-concept effort, suggesting the need for further research into the role of wearable sensors in early illness detection.

Researchers used the commercially available Oura Ring smart device to collect all physiological data.

TOP-LINE DATA

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

The temperature data collected by the Oura Ring was able to reliably detect the onset of fevers, one of the most common symptoms associated with COVID-19 and the flu. In the study, the ring detected early signs of fever in 93% of the cases an average of three days before symptoms showed.

Because the wearable could detect the onset of illness using digital biomarkers when some participants didn’t report symptoms, researchers believed that wearables could pose an important role in identifying asymptomatic cases.

This is particularly significant for COVID-19 because as many as 40% of infections are asymptomatic, according to the Centers for Disease Control and Prevention’s current best estimate.

The study also supported the importance of longitudinal, high temporal-resolution data gathered within individuals instead of single time-point measures.

A person’s temperature varies throughout the day, so spot checks offer about the same reliability of catching a syllable per minute in a conversation, rather than whole sentences, according to Benjamin Smarr, a corresponding author for the paper.

Researchers concluded that using multiple biomarkers provide superior illness prediction than single-metric models. When they looked at changes in participants’ temperature, other biomarkers were also impacted, such as heart rate, heart rate variability and respiratory rate.

However, the authors noted that the changes were not always an exact corresponding match. Meaning that sometimes a person’s temperature would spike, but not their heart rate, and vice versa.

“The key challenges can be summarized as follows: people are different, and so are physiological systems,” the authors said in the paper. “Taking examples displayed within this manuscript, the amplitude of daily rhythm, stability across days, correlation across variables, and stability of those correlations all change within and across individuals, both in and out of reported illness.”

METHODS

The 50 subjects all owned Oura rings and had had COVID-19 before joining the study.

Most participants (66%) lived in the United States, with an additional six participants in the U.K., three in Finland, and one each in Austria, Canada, Germany, Honduras, Italy, The Netherlands, Norway and Sweden.

A majority (66%) identified as male and the average age was 43.7 years. Of the 48 participants who indicated their race or ethnicity, the majority (81%) identified as Caucasian or White, eight as Hispanic or Latino, one as Middle Eastern, one as Asian, one as South Asian and three as “other.”

THE LARGER TREND

This report represents early findings from the larger TemPredict study, which includes 65,000 participants with the goal of developing an algorithm that can predict the onset of symptoms such as fever, cough and fatigue, which are characteristic of COVID-19. Researchers say they hope to achieve that goal by the end of the year.

Oura Rings are also being used in the DETECT (Digital Engagement & Tracking for Early Control & Treatment) Study, headed by the Scripps Research Translational Institute. The project aims to not only identify areas with viral outbreaks such as COVID-19 more quickly but to “develop more individualized approaches to health care” using person-specific vital-sign readings, according to the study’s enrollment website.

The health tracker Fitbit also recently released findings from its study that used biometrics to predict the onset of COVID-19. It outlines predictors for the severity of illness, symptom prevalence, illness duration among male and female participants and estimations of the need for hospitalization.

Notably, the Fitbit study found that fevers were only present in 59.4% of males and 52% of females, indicating that temperature screening alone may not be enough to measure infection rates.

Outside of research, this year Oura raised $28 million in a Series B funding round. It also partnered with both the NBA and WNBA to help players and staff monitor their health while they completed their seasons.

ON THE RECORD

“If wearables allow us to detect COVID-19 early, people can begin physical isolation practices and obtain testing so as to reduce the spread of the virus,” said Ashley Mason the principal investigator of the study, in a statement. “In this way, an ounce of prevention may be worth even more than a pound of cure.”

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Medtronic Scoops up Gesture-tracking Startup Klue to Bolster Personalized Closed Loop SystemMedtronic Scoops up Gesture-tracking Startup Klue to Bolster Personalized Closed Loop System
  • The next era of hospital, healthtech and outsourced provider partnershipsThe next era of hospital, healthtech and outsourced provider partnerships
  • Alaya.bio Acquires Key Assets From Ixaka France, Accelerating the Progress of Its Novel In Vivo CAR-T Immunotherapy PlatformAlaya.bio Acquires Key Assets From Ixaka France, Accelerating the Progress of Its Novel In Vivo CAR-T Immunotherapy Platform
  • HMS’s $36M Deal To Buy VitreosHealth Combines Complementary FirmsHMS’s $36M Deal To Buy VitreosHealth Combines Complementary Firms
  • Asia-Pacific Respiratory Device Industry Insights, 2019-2025 – Key Players are ResMed, Cipla, GlaxoSmithKline, 3M, Novartis, and Omron HealthcareAsia-Pacific Respiratory Device Industry Insights, 2019-2025 – Key Players are ResMed, Cipla, GlaxoSmithKline, 3M, Novartis, and Omron Healthcare
  • Puerto Rico’s First Home Delivery Pharmacy Launches During COVID-19 CrisisPuerto Rico’s First Home Delivery Pharmacy Launches During COVID-19 Crisis
  • Livongo for Diabetes Solution Now Available to New Jersey State and School Health Plan MembersLivongo for Diabetes Solution Now Available to New Jersey State and School Health Plan Members
  • Medbelle Offering COVID-19 Tests to Patients in the UK at CostMedbelle Offering COVID-19 Tests to Patients in the UK at Cost

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications